Nanotechnology and COVID-19: quo vadis?

被引:7
作者
Tavares, Joao Lima [1 ,2 ]
Cavalcanti, Iago Dillion Lima [1 ,2 ]
Santos Magalhaes, Nereide Stela [1 ]
Lira Nogueira, Mariane Cajuba de Britto [1 ,2 ]
机构
[1] Univ Fed Pernambuco UFPE, Lab Imunopatol Keizo Asami LIKA, Av Prof Moraes Rego,Cidade Univ, BR-12355067 Recife, PE, Brazil
[2] Univ Fed Pernambuco CAV UFPE, Ctr Acad Vitoria, Lab Nanotecnol Biotecnol & Cultura Celulas, Recife, PE, Brazil
关键词
COVID-19; Nanomedicine; Nanocarriers; Liposomes; Nanoparticles; DRUG-DELIVERY; VACCINE; CHALLENGES;
D O I
10.1007/s11051-022-05452-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The pandemic COVID-19 has worried everyone due to the high mortality rate and the high number of people hospitalized with severe acute respiratory syndrome caused by SARS-CoV-2. Given the seriousness of this disease, several companies and research institutions have sought alternative treatment and/or prevention methods for COVID-19. Due to its versatility, nanotechnology has allowed the development of protective equipment and vaccines to prevent the disease and reduce the number of severe COVID-19 cases. Thus, this article combined the main works and products developed in a nanotechnological field for COVID-19. We performed a literature search using the keywords "COVID-19," "SARS-CoV-2," "nanoparticles," "nanotechnology," and "liposomes" in the SciELO, Scifinder, PubMed, Sciencedirect, ClinicalTrials, and Nanotechnology Products databases Database. The data survey indicated 48 articles, 62 products, and 32 patents. The use of nanotechnology against COVID-19 has brought benefits in several parameters of this disease, helping develop rapid diagnostic tests that release the result in 10 min, as well as developing vaccines containing genetic material from SARS-CoV-2 (DNA, mRNA, and protein subunits). Nanotechnology is an exceptional ally against COVID-19, contributing to the most diverse areas, helping both prevent, diagnose, and treat COVID-19.
引用
收藏
页数:22
相关论文
共 78 条
[1]   COVID-19 vaccines: the pandemic will not end overnight [J].
不详 .
LANCET MICROBE, 2021, 2 (01) :E1-E1
[2]  
[Anonymous], 2020, PATENTED ANTIMICROBI
[3]   Nanoparticles in the clinic: An update [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2019, 4 (03)
[4]   SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis-An updated review [J].
Bhat, Eijaz Ahmed ;
Khan, Johra ;
Sajjad, Nasreena ;
Ali, Ahmad ;
Aldakeel, Fahad M. ;
Mateen, Ayesha ;
Alqahtani, Mohammed S. ;
Syed, Rabbani .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
[5]   Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date [J].
Bobo, Daniel ;
Robinson, Kye J. ;
Islam, Jiaul ;
Thurecht, Kristofer J. ;
Corrie, Simon R. .
PHARMACEUTICAL RESEARCH, 2016, 33 (10) :2373-2387
[6]   NOVAVAX OFFERS FIRST EVIDENCE THAT COVID VACCINES PROTECT PEOPLE AGAINST VARIANTS [J].
Callaway, Ewen ;
Mallapaty, Smriti .
NATURE, 2021, 590 (7844) :17-17
[7]   Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials [J].
Caster, Joseph M. ;
Patel, Artish N. ;
Zhang, Tian ;
Wang, Andrew .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2017, 9 (01)
[8]   Pharmaceutical nanotechnology: which products are been designed against COVID-19? [J].
Cavalcanti, Iago Dillion Lima ;
Cajuba de Britto Lira Nogueira, Mariane .
JOURNAL OF NANOPARTICLE RESEARCH, 2020, 22 (09)
[9]   Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19 [J].
Cavalcanti, Iago Dillion Lima ;
Medeiros, Sandrelli Meridiana de Fatima Ramos dos Santos ;
Macedo, Daniel Charles dos Santos ;
Cavalcanti, Isabella Macario Ferro ;
Nogueira, Mariane Cajuba de Britto Lira .
CURRENT DRUG DELIVERY, 2021, 18 (05) :583-595
[10]   Nano Research for COVID-19 [J].
Chan, Warren C. W. .
ACS NANO, 2020, 14 (04) :3719-3720